Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$8.02−0.60 (-6.96%)

Close on Nov 12, 2026Market cap $291.06MP/E –Yield –

Evommune profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Evommune's profit margin for the twelve months ending Jun 30, 2026 was -946.7%. For fiscal 2025 it was -529.8%, against -954.4% the year before.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-529.8%	+424.6
FY2024	Dec 31, 2024	-954.4%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2025	Sep 30, 2025	-124.8%	–
Q1 FY2025	Mar 31, 2025	-485.2%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVMN.

Revenue growth-100.0% · median 320.4%

Advertisement
300 × 250

See a number that looks wrong?